Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sirolimus in Combination With MEC in High Risk Myeloid Leukemias (UPCC 02407)

This study has been completed.
Information provided by:
University of Pennsylvania Identifier:
First received: October 24, 2008
Last updated: September 29, 2010
Last verified: September 2010

The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high risk myeloid leukemias.

Condition Intervention Phase
Myeloid Leukemias
Drug: Rapamycin, Mitoxantrone, Etoposide, Cytarabine
Drug: Rapamycin + MEC
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias

Resource links provided by NLM:

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Assessment of biologic effects of rapamycin on mTOR targets such as p70 protein phosphorylation in leukemic cells [ Time Frame: Study conclusion ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Safety of the sirolimus + MEC regimen [ Time Frame: Study conclusion ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 15
Study Start Date: July 2007
Study Completion Date: June 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rapamycin + MEC Drug: Rapamycin, Mitoxantrone, Etoposide, Cytarabine
Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
Drug: Rapamycin + MEC
Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have histologic evidence of advanced myeloid leukemias defined as one of the following: primary refractory non-M3 AML; relapsed non-M3 AML; secondary AML; intermediate or poor prognosis de novo AML in patients who are >= 60 years old
  • >= 18 years of age
  • ECOG performance status of 0, 1
  • Able to consume oral medication
  • Initial laboratory values: creatinine <= 2.0 mg/dL; total or direct bilirubin <= 1.5/dL; SGPT(ALT) <= 3xULN; negative pregnancy test for women with child-bearing potential
  • Ejection fraction of >= 45%

Exclusion Criteria:

  • Subjects with FAM B3
  • Must not be receiving chemotherapy (except Hydroxyurea)
  • Not receiving growth factors, except for erythropoietin
  • Subjects with a "currently active" second malignancy other than non-melanoma skin cancers
  • Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, MI within the last 6 months or uncontrolled cardiac arrhythmia
  • Subjects taking diltiazem
  • Subjects who require HIV protease inhibitors or those with AIDS-related illnesses
  • No evidence of cerebellar dysfunction at baseline or during prior cytarabine therapy
  • Not pregnant or breastfeeding
  • Uncontrolled infection
  • Subjects taking Carbamazepine, Rifabutin, Rifampin, Rifapentine, St. John's wort, Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Telithromycin, Verapamil, Tacrolimus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00780104

United States, Pennsylvania
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
  More Information

No publications provided

Responsible Party: Selina Luger, M.D., University of Pennsylvania Abramson Cancer Center Identifier: NCT00780104     History of Changes
Other Study ID Numbers: UPCC 02407
Study First Received: October 24, 2008
Last Updated: September 29, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Pennsylvania:
Advanced myeloid leukemias
Relapsed myeloid leukemias
Refractory myeloid leukemias

Additional relevant MeSH terms:
Leukemia, Myeloid
Neoplasms by Histologic Type
Etoposide phosphate
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Central Nervous System Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 27, 2014